This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Opie, L. H. Search for Related Content PubMed PubMed Citation Articles by Opie, L. H. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Heart Attack Related Collections Acute myocardial infarction

(Circulation. 2008;117:2172-2177.)
© 2008 American Heart Association, Inc.

Editorial

Metabolic Management of Acute Myocardial Infarction Comes to the Fore and Extends Beyond Control of Hyperglycemia

Lionel H. Opie, MD, DSc, DPhil

From the Hatter Cardiovascular Research Institute, Department of Medicine, University of Cape Town, South Africa.

Correspondence to Lionel H. Opie, Hatter Cardiovascular Research Institute, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, 7925 Cape Town, South Africa. E-mail Lionel.Opie@uct.ac.za

Key Words: Editorials • myocardial infarction • hyperglycemia • glucose metabolism disorders • fatty acids, nonesterified

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Acute myocardial infarction (AMI) is an acute metabolic stress, as has been recognized for at least 40 years.^1,2 Its components include a rapid rise in plasma catecholamines, plasma free fatty acids, and blood glucose within the first 1 to 2 hours of onset of symptoms.³ Recent attention has focused on the possible adverse effects of hyperglycemia,⁴ now thought to have adverse effects in its own right, such as formation of oxygen free radicals⁵ and consequent adverse inflammatory response.^6,7 Therefore, the level A recommendation of the American Heart Association (AHA) Diabetes Committee is that glucose levels should be measured in all patients with suspected or confirmed acute coronary syndromes (ACS). There follows, perhaps with a little less conviction (level of evidence B), the proposal that intensive glucose control may be considered if plasma glucose is >180 mg/dL (10 mmol/L) or even if the degree of hyperglycemia is less (level C). The recommendation to use intravenous insulin is based on extrapolation from other patient populations in acute intensive care,^8,9 and a wise call is made for further studies to define the best approach to glucose control in patients with ACS.

See Circulation. 2008:117:1610–1619

These recommendations raise several challenges, each of which merits closer examination. This Editorial will argue the case for a broader view of the relationship between glucose metabolism and ACS, with particular analysis of the proposal that it is the high adrenergic mediated levels of free fatty acids (FFAs or nonesterified fatty acids [NEFAs]) that may be the major lethality . . . [Full Text of this Article]

This article has been cited by other articles:

				L. H. Opie and J. Knuuti The adrenergic-Fatty Acid load in heart failure. J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1637 - 1646. [Abstract] [Full Text] [PDF]

				M. Kosiborod, S. E. Inzucchi, H. M. Krumholz, F. A. Masoudi, A. Goyal, and J. A. Spertus Is Insulin the Preferred Compound in Lowering Glucose Levels in Patients After a Myocardial Infarction?--Reply Arch Intern Med, September 28, 2009; 169(17): 1637 - 1638. [Full Text] [PDF]

				R. Marfella, C. Di Filippo, M. Portoghese, F. Ferraraccio, M. R. Rizzo, M. Siniscalchi, E. Musacchio, M. D'Amico, F. Rossi, and G. Paolisso Tight Glycemic Control Reduces Heart Inflammation and Remodeling During Acute Myocardial Infarction in Hyperglycemic Patients J. Am. Coll. Cardiol., April 21, 2009; 53(16): 1425 - 1436. [Abstract] [Full Text] [PDF]

				A. Goyal, K. Nerenberg, H. C Gerstein, G. Umpierrez, and P. W. Wilson Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points Diabetes and Vascular Disease Research, November 1, 2008; 5(4): 276 - 284. [Abstract] [PDF]